Navigation Links
U-M researchers find key interaction that controls telomeres
Date:2/16/2010

ANN ARBOR, Mich. In the dominoes that make up human cells, researchers at the University of Michigan Comprehensive Cancer Center have traced another step of the process that stops cells from becoming cancerous.

It starts with the enzyme telomerase, which affects the caps, or telomeres, at the end of a chromosome. Telomeres shorten over time. But telomerase prevents this from happening, making the cell immortal. If cancer is triggered in the cell, the presence of telomerase leads to the growth of the cancer.

Telomerase is kept in control by the protein TRF1, which keeps the telomeres operating correctly. But another protein, Fbx4, can bind to TRF1 and degrade it, causing the telomeres to lengthen.

Now, researchers have discovered, a third protein, TIN2, can step in and override Fbx4 by binding to TRF1 first and preventing Fbx4 from attaching to it.

This finding paves the way for developing a drug that acts like TIN2, keeping everything in check and stopping the first domino from falling.

Results of the study appear in the Feb. 16 issue of Developmental Cell.

"In 90 percent of cancers, no matter what caused the cancer to form, it needs telomerase activity to maintain the cell. Without telomerase, the cell will die. Our work is key to understanding a detailed mechanism for how these molecules interact and how to design a drug to block Fbx4," says senior author Ming Lei, Ph.D., assistant professor of biological chemistry at the University of Michigan Medical School.

The researchers found that the location in the molecule where Fbx4 binds to TRF1 overlaps with where TIN2 binds to TRF1. Where both Fbx4 and TIN2 are present, the TIN2 wins out and binds to the TRF1 first. This blocks Fbx4 from binding to the TRF1, thereby stabilizing TRF1 and keeping the telomere length in control.

The researchers are now looking at peptides that mimic TIN2's binding to TRF1, in order to block Fbx4. The work is still in preliminary stages and no new therapies are being tested in patients.

If a drug is discovered, it could impact all cancer types. Currently, molecularly targeted therapies address a pathway or gene that's involved in only specific types of cancer. But telomerase is involved in all types of cancer.

"If we find a drug that can inhibit telomerase activity in any fashion, that could be a universal cancer drug," says Lei, a Howard Hughes Medical Institute Early Career Scientist.


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert  

Related biology news :

1. Researchers identify proteins involved in new neurodegenerative syndrome
2. Texas researchers and educators head for Antarctica
3. MGH researchers describe new way to identify, evolve novel enzymes
4. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
5. U of MN researchers discover noninvasive diagnostic tool for brain diseases
6. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
7. Researchers discover new strategies for antibiotic resistance
8. Researchers find new taste in fruit flies: carbonated water
9. Binghamton University researchers investigate evolving malaria resistance
10. UIC researchers find promising new targets for antibiotics
11. Researchers develop simple method to create natural drug products
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
U-M researchers find key interaction that controls telomeres
(Date:1/6/2017)... Jan. 5, 2017  Delta ID Inc., a leader ... technology for automotive at CESĀ® 2017. Delta ID has ... to demonstrate the use of iris scanning as a ... the driver in a car, and as a way ... experience. Delta ID and Gentex will demonstrate ...
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ), ... HealthCare, and Finance sectors announced today that Leaders in Community Alternatives ... deploy a community-based supportive services program to reduce recidivism in a ... its presence in the state. ... This new program, which is expected to commence in ...
(Date:12/16/2016)... Research and Markets has announced the addition of the ... report to their offering. ... The biometric vehicle access system market, in terms ... from 2016 to 2021. The market is estimated to be USD ... by 2021. The growth of the biometric vehicle access system market ...
Breaking Biology News(10 mins):
(Date:1/14/2017)... -- The Alliance for Safe Biologic Medicines (ASBM) today issued ... guidance on biologic naming: We commend ... importance of distinct naming for all biologics, including biosimilars. ... will bring to patients, including new treatment options and ... the Guidance dealing with suffix design remains at odds ...
(Date:1/13/2017)... Staten Island, NY (PRWEB) , ... January 13, ... ... products to meet every cuvette-related demand that it has found among its diverse ... electroporation cuvettes for use in most brands electroporators including BTX and Bio-Rad. ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... performing routine electrochemical biosensing has increased dramatically. Primarily driven by the medical ... quantification of various analytes in complex samples. , Screen-printed electrodes ...
(Date:1/12/2017)... Conn. , Jan. 12, 2017   ... company and maker of Flublok Influenza Vaccine ... Zika vaccine candidate had good safety results and ... in preclinical studies. The product is expected to ... few months.  In addition, the Institute of Technology ...
Breaking Biology Technology: